Active substance
Results for the substance insulin degludec+liraglutide
1 result
About this active substance
The combination of insulin degludec and liraglutide is used for the treatment of type 2 diabetes in adults. Insulin degludec provides long-term glycemic control, while liraglutide, a GLP-1 receptor agonist, helps reduce postprandial blood sugar levels and supports weight loss.
The medication is administered as a subcutaneous injection, once daily at the same time, as directed by a doctor. It is important for patients to regularly monitor blood sugar levels and adhere to the treatment regimen.
Patients should be aware of potential side effects, such as hypoglycemia, nausea, or injection site reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include hypoglycemia, nausea, and injection site reactions. In rare cases, severe reactions such as pancreatitis or allergic reactions may occur. Patients should be informed of these risks before use.
The medication is administered as a subcutaneous injection, once daily at the same time, as directed by a doctor. It is important for patients to regularly monitor blood sugar levels and adhere to the treatment regimen.
Patients should be aware of potential side effects, such as hypoglycemia, nausea, or injection site reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include hypoglycemia, nausea, and injection site reactions. In rare cases, severe reactions such as pancreatitis or allergic reactions may occur. Patients should be informed of these risks before use.